Voyager Therapeutics Inc

NASDAQ:VYGRUnited States

Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.

Contact Information

Headquarters

75 Hayden AvenueLEXINGTON, MA, United States 02421

Phone

857-259-5340

Fax

302-655-5049

Executives

Independent Chairman of the Board

Michael Higgins

Director

Alfred Sandrock

Chief Operating Officer, Principal Financial Officer, Principal Accounting Officer

Robin Swartz

Chief Scientific Officer

Todd Carter

Chief Legal Officer

Jacquelyn Fahey Sandell